| advanced breast cancer (metastatic) | All results are NS for efficacy inferior to tamoxifen in terms of diarrhoea in Buzdar a, 1996 inferior to tamoxifen in terms of Clinical benefit (assessable) in Milla-Santos, 2003 inferior to tamoxifen in terms of Clinical benefit (randomised) in Milla-Santos, 2003 | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| TARGET (Bonneterre), 2001 | vs tamoxifen | thromboembolic 0.55 [0.31; 0.97] | | Clinical benefit (assessable) 0.91 [0.81; 1.02] Objective response (assessable) 0.93 [0.77; 1.14] vomiting 1.07 [0.69; 1.65] diarrhoea 1.22 [0.79; 1.91] overall survival (reported or calculated) 0.97 [0.53; 1.77] nausea 0.90 [0.70; 1.15] progression-free survival (reported or calculated) 0.82 [0.48; 1.40] Objective response (randomised) 0.93 [0.77; 1.14] Clinical benefit (randomised) 0.91 [0.81; 1.02] vaginal bleeding 0.46 [0.16; 1.31] hot flushes 1.15 [0.93; 1.42] | | Buzdar a, 1996 | vs tamoxifen | | diarrhoea 3.17 [1.39; 7.26] | Clinical benefit (assessable) 0.96 [0.78; 1.17] Objective response (assessable) 0.98 [0.62; 1.55] vomiting 1.53 [0.86; 2.74] overall survival (reported or calculated) 0.78 [0.39; 1.57] nausea 1.39 [0.91; 2.11] Objective response (randomised) 0.98 [0.62; 1.55] Clinical benefit (randomised) 0.96 [0.78; 1.17] thromboembolic 0.72 [0.31; 1.69] vaginal bleeding 0.48 [0.20; 1.18] rash 0.74 [0.39; 1.38] hot flushes 1.56 [0.93; 2.62] | | Mauriac, 2003 | vs tamoxifen | | | Clinical benefit (assessable) 1.06 [0.91; 1.24] Objective response (assessable) 1.16 [0.87; 1.55] vomiting 0.91 [0.64; 1.30] diarrhoea 1.32 [0.87; 2.01] nausea 0.97 [0.77; 1.22] progression-free survival (reported or calculated) 1.34 [0.79; 2.28] Objective response (randomised) 1.16 [0.87; 1.55] Clinical benefit (randomised) 1.06 [0.91; 1.24] thromboembolic 1.13 [0.57; 2.24] rash 1.33 [0.80; 2.22] hot flushes 0.98 [0.75; 1.27] | | Milla-Santos, 2003 | vs tamoxifen | | Clinical benefit (assessable) 0.67 [0.56; 0.81] Clinical benefit (randomised) 0.67 [0.56; 0.81] | Objective response (assessable) 0.75 [0.51; 1.10] overall survival (reported or calculated) 0.92 [0.43; 1.98] Objective response (randomised) 0.75 [0.51; 1.10] |
| Trial | Treatments | Patients | Method |
|---|
| TARGET (Bonneterre), 2001 | anastrozole
1 mg once daily (n=340) vs. tamoxifen 20 mg
once daily (n=328) | first-line therapy for advanced breast cancer in 353 postmenopausal women | Parallel groups Sample size: 340/328 Primary endpoint: TTP FU duration: | | Buzdar a, 1996 | (n=-9) vs. (n=-9) | postmenopausal patients with advanced breast cancer | Sample size: -9/-9 Primary endpoint: FU duration: | | Mauriac, 2003 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Milla-Santos, 2003 | (n=-9) vs. (n=-9) | -line therapy in postmenopausal, hormone-dependent, advanced breast cancer | Sample size: -9/-9 Primary endpoint: FU duration: |
|
